1. 188PDImpact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). (23rd October 2018) Authors: Untch, M; Jackisch, C; Schneeweiss, A; Schmatloch, S; Aktas, B; Denkert, C; Schem, C; Wiebringhaus, H; Kümmel, S; Rhiem, K; Warm, M; Fasching, P A; Just, M; Hanusch, C; Hackmann, J; Blohmer, J-U; Furlanetto, J; Nekljudova, V; von Minckwitz, G; Loibl, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 323PSubcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis. (23rd October 2018) Authors: Kümmel, S; Tondini, C A; Abraham, J; Nowecki, Z I; Itrych, B; Hitre, E; Karaszewska, B; Juarez, A; Morales-Vásquez, F; Pérez García, J M; Cardona-Huerta, S; Heinzmann, D; He, J; Duc, A N; Crepelle-Fléchais, A; Martín, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. (16th May 2019) Authors: Loibl, S; Untch, M; Burchardi, N; Huober, J; Sinn, B V; Blohmer, J -U; Grischke, E -M; Furlanetto, J; Tesch, H; Hanusch, C; Engels, K; Rezai, M; Jackisch, C; Schmitt, W D; von Minckwitz, G; Thomalla, J; Kümmel, S; Rautenberg, B; Fasching, P A; Weber, K Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1279 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LBA13Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. (23rd October 2018) Authors: Gluz, O; Nitz, U; Liedtke, C; Christgen, M; Grischke, E-M; Forstbauer, H; Braun, M; Warm, M; Hackmann, J; Uleer, C; Aktas, B; Schumacher, C; Lindner, C; Kümmel, S; Kates, R E; Potenberg, J; Staib, P; Wuerstlein, R; Kreipe, H H; Harbeck, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Surgical treatment of primary breast cancer in the neoadjuvant setting. Issue 8 (19th May 2014) Authors: Kümmel, S; Holtschmidt, J; Loibl, S Journal: British journal of surgery Issue: Volume 101:Issue 8(2014:Aug.) Page Start: 912 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto. (18th October 2018) Authors: Loibl, S; Weber, K E; Timms, K M; Elkin, E P; Hahnen, E; Fasching, P A; Lederer, B; Denkert, C; Schneeweiss, A; Braun, S; Salat, C T; Rezai, M; Blohmer, J U; Zahm, D M; Jackisch, C; Gerber, B; Klare, P; Kümmel, S; Schem, C; Paepke, S Journal: Annals of oncology Issue: Volume 29:Number 12(2018) Page Start: 2341 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗